Agency Forms Undergoing Paperwork Reduction Act Review, 41441-41442 [2024-10358]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 93 / Monday, May 13, 2024 / Notices
Laboratory Developed Tests Workgroup
Update; and (7) Drug Shortage
Workgroup Update. Agenda items are
subject to change as priorities dictate.
Public Participation
Written Public Comment: Members of
the public are welcome to submit
written comments in advance of the
meeting. Written comments must be
submitted by emailing nchhstppolicy@
cdc.gov with subject line ‘‘ACET June
2024 Public Comment Registration’’ by
July 2, 2024.
Oral Public Comment: Individuals
who would like to make an oral
comment during the public comment
period must register by emailing
nchhstppolicy@cdc.gov with subject
line ‘‘ACET June 2024 Public Comment
Registration’’ by June 18, 2024. The
public comment period is on June 26,
2024, at 10:15 a.m., EDT.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–10300 Filed 5–10–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–23HS]
lotter on DSK11XQN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘National
Survey of Syringe Services Programs
(NSSSP)’’, to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on May 4,
2023, to obtain comments from the
public and affected agencies. CDC
received two public comments related
to the previous notice. This notice
VerDate Sep<11>2014
21:33 May 10, 2024
Jkt 262001
serves to allow an additional 30 days for
public and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Program Evaluation for PS22–2208
Component 2—New—National Center
for HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention, Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
PS22–2208 Component 2
(Strengthening Syringe Services
Programs) serves as a coordinated and
accountable mechanism for distribution
of funding to syringe services programs
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
41441
(SSPs) to support implementation and
expansion of services in areas of the
United States, Territories, and Tribal
Nations disproportionately affected by
infectious disease consequences of
injection drug use. Project activities will
directly contribute to establishing and
expanding a national SSP infrastructure
and prevention of infectious disease
consequences of drug use. CDC has
funded the National Alliance of State
and Territorial AIDs Directors
(NASTAD) to implement this project.
NASTAD, in partnership with
University of Washington will collect
monitoring and evaluation data from
funded SSPs through their internal
mechanisms, both for their internal
evaluation as well as to report semiannual and annual project performance
reports and stratified aggregate data to
CDC. The primary purpose of this
information collection is to monitor and
evaluate the PS22–2208 Component 2
funding opportunity’s overall goal of
supporting SSP subrecipients in
meeting the needs of people who use
drugs (PWUD) and reducing infectious
disease and other harms related to drug
use.
During the first year of this
Cooperative Agreement, all PS22–2208
SSP subrecipients will be sent a 25minute baseline program evaluation
survey at the start of project
implementation, and a 15-minute
quarterly program evaluation survey in
the following three quarters of the
project period. For Years 2–5, new
PS22–2208 SSP subrecipients will be
sent the baseline survey at the start of
project implementation, and all existing
subrecipients will receive the quarterly
program evaluation survey in the
following three quarters of the project
period. SSP subrecipients will primarily
complete the survey online in REDCap,
with options to complete via telephone
or videoconferencing modalities.
Subrecipients will be asked to complete
the surveys within one month of receipt
and will receive weekly reminders until
the survey is complete. SSP
subrecipients may be reminded
informally during meetings with
NASTAD and may also work with their
NASTAD point-of-contact to determine
an alternate method of survey
completion. The survey will include
questions on operational and
programmatic characteristics, and
quantity of prevention and treatment
services provided in-person, through
tele-health, and through navigation to
off-site care, during the specified
evaluation period.
Approximately 200 SSPs will
participate in the survey. We estimate
that it will take 70 minutes for each SSP
E:\FR\FM\13MYN1.SGM
13MYN1
41442
Federal Register / Vol. 89, No. 93 / Monday, May 13, 2024 / Notices
to complete the baseline survey and
three quarterly surveys, regardless of
how the respondent chooses to
complete it (i.e., self-administered
online or NASTAD staff-administered
by phone or videoconferencing). CDC
requests OMB approval for an estimated
233 annual burden hours. There is no
cost to survey participants other than
their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Respondent
All participating SSPs .....................................
All participating SSPs .....................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–10358 Filed 5–10–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Board of Scientific
Counselors, National Center for Injury
Prevention and Control
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
Notice of open and closed
meeting.
ACTION:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Board of
Scientific Counselors, National Center
for Injury Prevention and Control (BSC,
NCIPC). This meeting will take place in
person and virtually and is partially
open to the public.
SUMMARY:
The meeting will be held on June
5, 2024, from 1 p.m. to 4 p.m., EDT
(Closed); and June 6, 2024, from 10 a.m.
to 3:30 p.m., EDT (Open). The public
comment period will be at the end of
the open session of the meeting on June
6, 2024, from 3:10 p.m. to 3:25 p.m.,
EDT.
DATES:
Centers for Disease Control
and Prevention, Chamblee Campus,
Building 106, Conference Room 1–B,
4770 Buford Highway NE, Atlanta,
Georgia 30341. The conference room
will have seating for approximately 100
people for the open session of the
meeting.
lotter on DSK11XQN23PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
21:33 May 10, 2024
Number of
respondents
Form
Jkt 262001
Strengthening Syringe Services Programs
Baseline Survey.
Strengthening Syringe Services Programs
Quarterly Survey.
Please note that the meeting location
is a federal facility and in-person access
is limited to United States citizens
unless prior authorizations, taking up to
30 to 60 days, have been made. Visitors
must follow all directions for access to
CDC facilities. Directions for visitors to
CDC, including safety requirements
related to COVID–19, are available at
https://www.cdc.gov/screening/
visitors.html.
If you wish to attend the open session
of the meeting in person, please submit
a request by email to Mrs. Tonia Lindley
at TLindley@cdc.gov at least 5 business
days in advance of the meeting.
If you wish to attend the open session
of the meeting virtually, please register
in advance by accessing the link at:
https://cdc.zoomgov.com/webinar/
register/WN_X5RXABmES3u_
tsbMJdSJkg. Instructions to access the
Zoom virtual meeting will be provided
in the link following registration.
FOR FURTHER INFORMATION CONTACT:
Christopher R. Harper, Ph.D.,
Designated Federal Officer, Board of
Scientific Counselors, National Center
for Injury Prevention and Control,
Centers for Disease Control and
Prevention, 4770 Buford Highway NE,
Mailstop S–1069, Atlanta, Georgia
30341. Telephone: (404) 718–8330;
Email: ncipcbsc@cdc.gov.
SUPPLEMENTARY INFORMATION: Portions
of the meeting referenced above will be
closed to the public in accordance with
provisions set forth in section 552b(c)(4)
and (6), Title 5, U.S.C., and the
Determination of the Director, Office of
Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for
Disease Control and Prevention (CDC),
pursuant to 5 U.S.C. 1009(d) (Pub. L.
92–463, as amended).
Purpose: The Board of Scientific
Counselors, National Center for Injury
Prevention and Control (BSC, NCIPC)
will: (1) conduct, encourage, cooperate
with, and assist other appropriate public
health authorities, scientific
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(hours)
200
1
25/60
200
3
15/60
institutions, and scientists in the
conduct of research, investigations,
experiments, demonstrations, and
studies relating to the causes and
strategies related to the prevention of
injury, overdose, and violence; (2) assist
States and other entities in preventing
intentional and unintentional injuries,
and to promote health and well-being;
and (3) make recommendations of grants
and cooperative agreements for research
and prevention activities related to
injury, overdose, and violence. The
BSC, NCIPC makes recommendations
regarding policies, strategies, objectives,
and priorities and reviews progress
toward injury, overdose, and violence
prevention. The Board also provides
advice on the appropriate balance of
intramural and extramural research and
provides guidance on the needs,
structure, progress, and performance of
intramural programs. Further, the Board
provides guidance on extramural
scientific program matters.
Additionally, the Board provides
second-level scientific and
programmatic review of applications for
research grants, cooperative agreements,
and training grants related to injury,
overdose, and violence prevention, and
recommends approval of projects that
merit further consideration for funding
support. The Board also provides
feedback and input on strategic plans,
resources, and priority publications
related to injury, overdose, and violence
prevention.
Matters to be Considered: The closed
session of the meeting (Day 1) will focus
on the secondary peer review of
extramural research grant applications
received in response to three (3) Notices
of Funding Opportunity: RFA–CE–22–
003—‘‘Rigorously Evaluating Programs
and Policies to Prevent Child Sexual
Abuse (CSA)’’; RFA–CE–24–012—
‘‘Rigorous Evaluation of Policy-Level
Interventions to Prevent Overdose
(R01)’’; and RFA–CE–24–030—
‘‘Research Grants for Preventing
E:\FR\FM\13MYN1.SGM
13MYN1
]]>Agencies
[Federal Register Volume 89, Number 93 (Monday, May 13, 2024)]
[Notices]
[Pages 41441-41442]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10358]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-24-23HS]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``National Survey of Syringe Services
Programs (NSSSP)'', to the Office of Management and Budget (OMB) for
review and approval. CDC previously published a ``Proposed Data
Collection Submitted for Public Comment and Recommendations'' notice on
May 4, 2023, to obtain comments from the public and affected agencies.
CDC received two public comments related to the previous notice. This
notice serves to allow an additional 30 days for public and affected
agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Program Evaluation for PS22-2208 Component 2--New--National Center
for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention, Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
PS22-2208 Component 2 (Strengthening Syringe Services Programs)
serves as a coordinated and accountable mechanism for distribution of
funding to syringe services programs (SSPs) to support implementation
and expansion of services in areas of the United States, Territories,
and Tribal Nations disproportionately affected by infectious disease
consequences of injection drug use. Project activities will directly
contribute to establishing and expanding a national SSP infrastructure
and prevention of infectious disease consequences of drug use. CDC has
funded the National Alliance of State and Territorial AIDs Directors
(NASTAD) to implement this project. NASTAD, in partnership with
University of Washington will collect monitoring and evaluation data
from funded SSPs through their internal mechanisms, both for their
internal evaluation as well as to report semi-annual and annual project
performance reports and stratified aggregate data to CDC. The primary
purpose of this information collection is to monitor and evaluate the
PS22-2208 Component 2 funding opportunity's overall goal of supporting
SSP subrecipients in meeting the needs of people who use drugs (PWUD)
and reducing infectious disease and other harms related to drug use.
During the first year of this Cooperative Agreement, all PS22-2208
SSP subrecipients will be sent a 25-minute baseline program evaluation
survey at the start of project implementation, and a 15-minute
quarterly program evaluation survey in the following three quarters of
the project period. For Years 2-5, new PS22-2208 SSP subrecipients will
be sent the baseline survey at the start of project implementation, and
all existing subrecipients will receive the quarterly program
evaluation survey in the following three quarters of the project
period. SSP subrecipients will primarily complete the survey online in
REDCap, with options to complete via telephone or videoconferencing
modalities. Subrecipients will be asked to complete the surveys within
one month of receipt and will receive weekly reminders until the survey
is complete. SSP subrecipients may be reminded informally during
meetings with NASTAD and may also work with their NASTAD point-of-
contact to determine an alternate method of survey completion. The
survey will include questions on operational and programmatic
characteristics, and quantity of prevention and treatment services
provided in-person, through tele-health, and through navigation to off-
site care, during the specified evaluation period.
Approximately 200 SSPs will participate in the survey. We estimate
that it will take 70 minutes for each SSP
[[Page 41442]]
to complete the baseline survey and three quarterly surveys, regardless
of how the respondent chooses to complete it (i.e., self-administered
online or NASTAD staff-administered by phone or videoconferencing). CDC
requests OMB approval for an estimated 233 annual burden hours. There
is no cost to survey participants other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondent Form Number of responses per per response
respondents respondent (hours)
----------------------------------------------------------------------------------------------------------------
All participating SSPs................ Strengthening Syringe 200 1 25/60
Services Programs
Baseline Survey.
All participating SSPs................ Strengthening Syringe 200 3 15/60
Services Programs
Quarterly Survey.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-10358 Filed 5-10-24; 8:45 am]
BILLING CODE 4163-18-P
